包括的な SRS Regenerex ティッシュ アタッチメント
包括的セグメント再ビジョンシステム (SRS) Regenerex 組織付着増強剤の安全性、性能、および臨床上の利点データを提供するための市販後臨床追跡調査 - 遡及的登録および前向き追跡調査の連続シリーズ研究
The objective of this retrospective and prospective consecutive series data collection is to confirm safety, performance, and clinical benefits of the Comprehensive SRS Regenerex Tissue Attachment Augments when used for limb salvage arthroplasty.
調査の概要
詳細な説明
Consecutive subjects implanted with Comprehensive SRS Regenerex Tissue Attachment Augments according to the approved indications, with the longest-term follow-up possible, will be identified and invited to participate in the study.
The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to the implant and/or procedure should be specified.
The study will include one site. There will be a maximum of 103 patients enrolled in the study.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Florida
-
Boca Raton、Florida、アメリカ、33432
- Toman Orthopedics and Sports Med
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Subjects must meet the inclusion criteria to be enrolled into the study. Subjects who meet any of the exclusion criteria should not be enrolled into the study.
The study population will comprise a consecutive cohort of up to 103 subjects implanted using the Comprehensive SRS Regenerex Tissue Attachment Augments.
説明
Inclusion Criteria:
-
Patient must be 18 years of age or older.
-
Patient must be willing and able to follow directions.
-
The Comprehensive Segmental Revision System was used in cases of:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
- Revision where other devices or treatments have failed.
- Correction of functional deformity.
- Oncology applications including bone loss due to tumor resection.
-
Proximal or total humeral replacement, for: Treatment of acute or chronic fractures with humeral head (shoulder) involvement, which are unmanageable using other treatment methods.
-
Distal or total humeral replacement for: Treatment of acute or chronic fractures with humeral epicondyle (elbow) involvement, which are unmanageable using other treatment methods.
-
Biomet Comprehensive Segmental Revision System was used in a reverse application in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff for proximal humeral replacement. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.
-
The Comprehensive Segmental Revision System was used with bone cement in distal humeral and total humeral applications.
-
Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision System
Exclusion Criteria:
-
Absolute contraindications:
- Infection
- Sepsis
- Osteomyelitis
- Patient is a prisoner
- Patient is a current alcohol or drug abuser
- Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
- Patient is unwilling to consent
-
Relative contraindications:
- Uncooperative patient or patient with neurologic disorders who is incapable of following directions
- Osteoporosis
- Metabolic disorders which may impair bone formation
- Osteomalacia
- Distant foci of infections which may spread to the implant site
- Vascular insufficiency, muscular atrophy, or neuromuscular disease
-
The Comprehensive Segmental Revision System was used in a reverse shoulder application in patients receiving radiation therapy
-
The Comprehensive Segmental Revision System was used without bone cement in distal humeral and total humeral applications.
-
Regenerex Tissue Attachment Augments weren't used during the patient's surgery
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Comprehensive Regenerex Tissue Attachment Augments
Regenerex Tissue Attachment Augments were used in combination with the Comprehensive Segmental Revision system |
Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Kaplan Meier Implant Survivorship
時間枠:Up to 10 Years
|
This will be established by recording the incidence and frequency of device revisions. Kaplan-Meier survival analysis is a statistical method that estimates survival rates over time and accounts for factors that can affect implant survival. |
Up to 10 Years
|
|
Safety Assessement
時間枠:Up to 10 Years
|
This will be established by recording the incidence and frequency of complications and adverse events. Relation of the events to the implant and/or procedure will be specified. |
Up to 10 Years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assessment of performance and clinical benefits by recording patient reported QuickDASH
時間枠:Up to 10 Years
|
QuickDASH, or Quick Disabilities of the Arm, Shoulder, and Hand, is a questionnaire that measures the impact of upper limb musculoskeletal disorders on physical function and symptoms. The QuickDASH has 11 items that cover six domains: Daily activities: How much difficulty the patient has performing physical activities Symptoms: How severe the patient's pain and tingling is Social function: How the patient's problem affects their social activities Work function: How the patient's problem affects their work Sleep: How the patient's problem affects their sleep Confidence: How the patient's problem affects their confidence Each item is rated on a 5-point Likert scale, with 1 being no difficulty and 5 being unable. The score is then converted to a 100-point scale, with 100 representing the greatest disability. |
Up to 10 Years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Erin Osborn、Zimmer Biomet
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD may not be shared due to this being a single center retrospective enrollment/prospective FUP with one single reference point. Additionally, data is being collected for EU regulatory purposes.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。